Sanctuary Advisors LLC Lowers Stake in Illumina, Inc. $ILMN

Sanctuary Advisors LLC lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 18.4% during the 1st quarter, Holdings Channel reports. The fund owned 20,592 shares of the life sciences company’s stock after selling 4,650 shares during the period. Sanctuary Advisors LLC’s holdings in Illumina were worth $2,538,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ILMN. Elyxium Wealth LLC purchased a new stake in shares of Illumina during the 4th quarter worth $25,000. Creative Capital Management Investments LLC grew its stake in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new position in Illumina in the fourth quarter valued at about $26,000. Laurel Wealth Advisors LLC bought a new position in Illumina in the fourth quarter worth about $26,000. Finally, Activest Wealth Management raised its holdings in Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 215 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Illumina

In other news, CAO Scott D. Ericksen sold 1,500 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the sale, the chief accounting officer directly owned 14,946 shares of the company’s stock, valued at $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the transaction, the insider directly owned 20,953 shares in the company, valued at approximately $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock worth $155,710,908 in the last three months. 2.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have commented on ILMN shares. Royal Bank Of Canada began coverage on shares of Illumina in a research report on Thursday, May 14th. They set an “outperform” rating and a $170.00 price target for the company. Piper Sandler boosted their price objective on shares of Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 1st. Citigroup increased their target price on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Wall Street Zen downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Guggenheim lifted their price target on shares of Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Nine research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $156.88.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $192.53 on Wednesday. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $196.66. The company has a market cap of $29.13 billion, a PE ratio of 35.01, a P/E/G ratio of 2.73 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The business has a 50-day simple moving average of $168.22 and a two-hundred day simple moving average of $144.20.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.22 EPS for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.